More recently it has been found that the CUL4-DDB1 complex can be modulated by binding of the drug, lenalidomide leading to degradation of lymphoid transcription factors IKZF1 and IKF3 in multiple myeloma cells (Fischer et al., 2014; Kronke et al., 2014). Here, DDB1 is linked to plasma cell myeloma.